Galderma is certainly the heavyweight for rosacea treatments and skincare. Rosacea sufferers will be familiar with Metrogel 1% and Oracea as well as their Cetaphil skincare range. More recently Galderma has gained approval for Mirvaso and also has CD5024/Ivermectin in development.
According to the Galderma AU web site, Mirvaso is now available in Australia. Here are the Australian versions of the MIRVASO Gel User Consumer Information and also Mirvaso Product Information. Mirvaso was first registered in the Australian Register of Therapeutic Goods on the 4th of August 2014. See the listing here – MIRVASO CMI Mirvaso […]
News today that the former owners of the patent covering the product Mirvaso have sued Galderma over a contract dispute. The 5 former owners of Sansrosa say that a contract error will cost them $20m. Sansrosa, who was then owned by Collagenex was sold to Galderma in 2008. Galderma asserts a group of patents protect […]
Users of ONRELTEA in Canada who have bad reactions or `adverse events’ related to using this newly approved product are reminded in the ONRELTEA Product Monograph to report these events. The body responsible for supervising prescription drugs is the Canada Vigilance Program. The Brimonidine based topical which is available in the US as Mirvaso has […]
Galderma has reached into its bag of trademarks and announced that Mirvaso will be known as ONRELTEA in Canada. Red Faced? Rosacea Sufferers Now Have a New Option Proven to Reduce Facial Redness Health Canada Approves The First and Only Topical Treatment Indicated for the Persistent Facial Erythema of Rosacea THORNHILL, ON, May 21, 2014 […]
Linda Stein Gold mentions in a video posted on Skin and Allergy News, referring to Galderma’s Ivermectin Cream ; Phase 3 Clinical Trials have completed, and FDA Approval is expected later this year (2014). This is great new for those who 1) want to try an approved treatment for demodex mites and 2) may not […]